A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

Blood Cancer J. 2019 Oct 1;9(10):80. doi: 10.1038/s41408-019-0240-6.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dexamethasone / administration & dosage
  • Dexamethasone / adverse effects
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Oligopeptides / administration & dosage
  • Oligopeptides / adverse effects
  • Progression-Free Survival
  • Thiadiazoles / administration & dosage
  • Thiadiazoles / adverse effects

Substances

  • Oligopeptides
  • Thiadiazoles
  • carfilzomib
  • Dexamethasone
  • filanesib